Agilent Technologies Inc vs L3Harris Technologies Inc — how do they compare? Agilent Technologies Inc trades at $148.38 (market cap $42.22B), while L3Harris Technologies Inc trades at $288.62 (market cap $53.26B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays the higher dividend (1.75%). Which is the better fit depends on your goals.
| A | LHX | |
|---|---|---|
Market Cap | $42.22B | $53.26B |
Sector | Health | Industrials |
52-Week High | $157.20 | $378.48 |
52-Week Low | $110.24 | $270.21 |
Enterprise Value | $43.77B | $63.71B |
Dividend Yield | 0.68% | 1.75% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.77, up 0.03% on the day, near its consensus price target of $154.90. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings beat expectations in Q1 2026, and the company maintains robust profitability with a 19.55% net income margin. Key developments include FDA and EU regulatory approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its biopharma portfolio.
Outlook remains positive with analyst consensus at Buy (77.5%) and a projected 4.1% upside to the price target. Risks include elevated valuation multiples (P/E 30.02) and dependence on healthcare sector growth. Earnings on August 26, 2026, will be critical for validating continued momentum amid competitive and macroeconomic pressures.
LHX trades at $285.18, down 1.57% today, with strong fundamental performance including three consecutive quarterly EPS beats and record $42 billion backlog. The company shows improving profitability with net margin expanding to 8.11% in 2026 projections. Recent defense contract wins and successful missile tests highlight operational momentum, though technical indicators show bearish pressure with price below key resistance levels.
LHX presents a compelling investment case with strong defense sector positioning, consistent earnings outperformance, and 72.7% analyst buy ratings targeting $319.33. Key risks include defense budget volatility and execution challenges in scaling production. The stock offers 12% upside to consensus target with dividend yield support, though near-term technical weakness requires monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →